Spruce Biosciences (SPRB) Competitors $0.29 0.00 (-0.10%) Closing price 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.10%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. IMRX, ONCY, CTMX, PDSB, KRON, VRPX, XFOR, CTOR, VNRX, and AADIShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Immuneering (IMRX), Oncolytics Biotech (ONCY), CytomX Therapeutics (CTMX), PDS Biotechnology (PDSB), Kronos Bio (KRON), Virpax Pharmaceuticals (VRPX), X4 Pharmaceuticals (XFOR), Citius Oncology (CTOR), VolitionRx (VNRX), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Immuneering Oncolytics Biotech CytomX Therapeutics PDS Biotechnology Kronos Bio Virpax Pharmaceuticals X4 Pharmaceuticals Citius Oncology VolitionRx Aadi Bioscience Spruce Biosciences (NASDAQ:SPRB) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do analysts recommend SPRB or IMRX? Spruce Biosciences currently has a consensus target price of $2.50, suggesting a potential upside of 754.12%. Immuneering has a consensus target price of $12.50, suggesting a potential upside of 727.81%. Given Spruce Biosciences' higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Immuneering.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Immuneering 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable valuation & earnings, SPRB or IMRX? Spruce Biosciences has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$7.10M1.70-$47.92M-$0.94-0.31Immuneering$320K169.34-$53.47M-$2.03-0.74 Does the MarketBeat Community prefer SPRB or IMRX? Spruce Biosciences received 4 more outperform votes than Immuneering when rated by MarketBeat users. However, 68.63% of users gave Immuneering an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote. CompanyUnderperformOutperformSpruce BiosciencesOutperform Votes3954.93% Underperform Votes3245.07% ImmuneeringOutperform Votes3568.63% Underperform Votes1631.37% Do institutionals and insiders hold more shares of SPRB or IMRX? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by company insiders. Comparatively, 25.0% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is SPRB or IMRX more profitable? Immuneering has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Immuneering N/A -79.19%-69.08% Which has more risk and volatility, SPRB or IMRX? Spruce Biosciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.32, indicating that its stock price is 132% less volatile than the S&P 500. Does the media favor SPRB or IMRX? In the previous week, Immuneering had 8 more articles in the media than Spruce Biosciences. MarketBeat recorded 8 mentions for Immuneering and 0 mentions for Spruce Biosciences. Immuneering's average media sentiment score of 1.01 beat Spruce Biosciences' score of 0.00 indicating that Immuneering is being referred to more favorably in the news media. Company Overall Sentiment Spruce Biosciences Neutral Immuneering Positive SummarySpruce Biosciences beats Immuneering on 10 of the 18 factors compared between the two stocks. Remove Ads Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.09M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-0.316.9923.2518.07Price / Sales1.70198.60361.2686.80Price / CashN/A65.6738.1634.64Price / Book0.165.926.493.99Net Income-$47.92M$142.37M$3.21B$247.18M7 Day Performance-7.81%-9.32%-6.42%-6.42%1 Month Performance-17.78%-10.26%-0.68%-7.44%1 Year Performance-64.47%-15.08%6.05%-4.31% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.3177 of 5 stars$0.29-0.1%$2.50+754.1%-65.5%$12.09M$7.10M-0.3120News CoverageGap DownIMRXImmuneering3.3432 of 5 stars$1.74-3.3%$11.00+532.2%-37.6%$54.03M$320,000.00-0.8860Short Interest ↓News CoveragePositive NewsGap DownONCYOncolytics Biotech1.2824 of 5 stars$0.63-0.1%$4.00+535.6%-51.2%$53.81MN/A-2.3330Gap DownCTMXCytomX Therapeutics4.0853 of 5 stars$0.67+0.4%$5.02+649.9%-71.6%$53.65M$138.10M3.94170Analyst DowngradeGap DownPDSBPDS Biotechnology1.7549 of 5 stars$1.37flat$11.67+751.6%-69.0%$52.32MN/A-1.1820Earnings ReportShort Interest ↓Gap DownKRONKronos Bio3.6916 of 5 stars$0.87-0.4%$1.63+87.5%-34.2%$52.30M$9.85M-0.61100Short Interest ↓VRPXVirpax Pharmaceuticals1.5161 of 5 stars$1.94-6.3%$3.00+54.6%-98.8%$51.53MN/A0.007Positive NewsGap DownTrading HaltedXFORX4 Pharmaceuticals4.4269 of 5 stars$0.30-4.0%$3.50+1,086.4%-83.5%$51.23M$1.12M-3.2880Analyst RevisionCTORCitius OncologyN/A$0.71+14.5%$3.00+322.5%N/A$50.80MN/A0.00N/AGap DownVNRXVolitionRx1.9228 of 5 stars$0.55-0.4%$3.75+584.3%-30.2%$50.78M$1.29M-1.5280Analyst ForecastGap DownAADIAadi Bioscience0.9509 of 5 stars$2.05+4.6%$1.67-18.7%-22.0%$50.63M$25.07M-0.9040 Remove Ads Related Companies and Tools Related Companies Immuneering Competitors Oncolytics Biotech Competitors CytomX Therapeutics Competitors PDS Biotechnology Competitors Kronos Bio Competitors Virpax Pharmaceuticals Competitors X4 Pharmaceuticals Competitors Citius Oncology Competitors VolitionRx Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRB Stock Free SPRB Stock Alerts